Aduro swept the IPO market with the combination immunotherapy, with an investment of 120 million US dollars

Source: Biovalley April 17, 2015 with the deepening of research, tumor immunotherapy has become a favorite of Wall Street investors Recently, aduro biotech, based in Berkeley, Calif., once again enjoyed the enthusiasm of investors in the IPO market The company issued 7 million shares at $17 per share in its recent IPO, sweeping $119 million from Wall Street Prior to that, the company had reached an agreement with pharmaceutical giant Johnson & Johnson to develop tumor immunotherapy According to the data released by the company, the funds raised will be mainly used to develop two immunotherapies, crs-207 and gvax Aduro is currently working on a combination of these two therapies for pancreatic cancer Aduro's combination therapy has also shown remarkable efficacy Last year, the FDA granted a breakthrough Drug Certification for the combination therapy This also ensures that once aduro completes this research, it will be able to push it to the market in the shortest time At present, the treatment is in the second phase of clinical research Aduro company recruited 240 patients for this purpose, and divided them into combination therapy group, crs-207 treatment group and traditional chemotherapy group The researchers took overall survival rate as the primary end point of the experiment, hoping to further prove the advantages of the combination of two immunotherapies and the effectiveness of this treatment scheme On the other hand, aduro also hopes to further consolidate the therapeutic effect of cancer by combining the latest drug achievements of the test point For this purpose, the company also designed a clinical phase II study to test the combined effect of crs-207 and gvax and Squibb's latest PD-1 drug opdivo It can be said that the IPO of aduro reflects the strong confidence in tumor immunotherapy in the US investment market From investment institutions to individuals, immunotherapy is regarded as an important tool for human beings to fight against cancer.